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SUMMARY
Background: Research suggests that women have higher mortality after acute myocardial infarction (AMI) than men. Potential 
factors to explain this disparity include delay to presentation, less aggressive interventional strategies, and more severe disease 
at coronary angiography in women.  
Methods: Consecutive patients (n=663) presenting to coronary care between Jan 2002 and Jan 2005 with ischemic type chest 
pain and AMI (troponin T >0.09ng/ml) were recruited. Details of the presentation and management were obtained from the 
medical notes. The primary endpoint was three month all cause mortality.  
Results: Of these patients 31% (205/663) were female. Mean age of women was 70 (SD 11) and 63 (SD 13) for men (p<0.001).   
There was no difference between the sexes for delay in presentation or treatment or for ST elevation infarction site.  Women 
had prior hypertension more than men (49% 100/205 vs. 38% 174/458, p=0.008). Women were less likely to have diagnostic 
catheterisation (67% 137/205 vs. 80% 365/458 p<0.001).  Both genders had similar coronary artery disease extent and frequencies 
of LV impairment (EF<45%) and were equally likely to undergo revascularisation (79% 108/137 vs. 81% 295/365 p=NS).  There 
was an excess 3 month mortality among women (11% 23/205 vs. 5% 24/458 in men p=0.006).
Independent predictors of 3 month mortality by logistic regression analysis were age (OR 1.06, 95% CI 1.03 -1.09, p<0.001) 
and LV impairment (OR 0.28, 95% CI 0.13-0.56, p<0.001).
Conclusion: As LV impairment was comparable in men and women, the excess mortality identified is due to older age at 
presentation of women.
INTRODUCTION
In this era of primary prevention in the cardiovascular field 
it is crucial that both health professionals and patients alike 
recognise  coronary  heart  disease  (CHD)  as  the  leading 
cause of death amongst women. Cardiovascular disease is 
responsible for one third of female mortality worldwide1. 
Public  health  initiatives  for  women  have  concentrated  on 
the “bikini cancers” with successful outcomes.  It follows 
therefore that highlighting issues associated with CHD in 
women could have widespread effects on the targeting of 
health service provision.  
Women are significantly more likely than men to die within 1 
year of myocardial infarction1-5.  Several reasons for this gender 
discrepancy in early mortality have been postulated. Of those 
patients diagnosed with myocardial infarction, the women 
are on average 8 years older than the men6-9. The diagnosis 
and management of CHD in women is therefore complicated 
by age associated comorbidities. Behavioural factors may 
play a role; the traditional role of the female as the care giver 
rather than care seeker has been implicated in their reluctance 
to seek medical assistance for the atypical symptoms that 
they often develop10. Women diagnosed with ischemic heart 
disease have greater frequencies of hypertension5,8,9,11 and 
diabetes mellitus3,6,8,9, 11,12 than their male counterparts. Also 
non  ST  elevation  MIs  (NSTEMI’s)  are  more  common  in 
women than in men10. This clearly adds to the difficulty in 
diagnosing AMI in women and further compounds delay to 
initiation of appropriate treatment10,13.  Several studies have 
demonstrated that the aggressive revascularisation strategies 
are less likely to be employed in women presenting with acute 
coronary syndromes9,10,11,14. 
The aim of this study was to clarify the differences in the 
presentation and management of AMI between males and 
females and to determine predictors of the excess mortality 
amongst women presenting to the Royal Victoria Hospital 
Belfast Coronary Care Unit.  
METHODS
Study patients 
The recruitment site has a doctor manned mobile coronary 
care unit, an Accident and Emergency department and is a 
tertiary facility with on site coronary angiography theatres © The Ulster Medical Society, 2008.
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and a regional cardiac surgery department.  The Coronary 
Care Myocardial Infarction Registry was used to identify 
consecutive patients presenting during 01 January 2002- 01 
January  2005  with  a  diagnosis  of  myocardial  infarction. 
Myocardial  infarction  was  defined  as  typical  ischemic  or 
atypical symptoms of at least 20 minutes duration with a 
cardiac Troponin T > 0.09ng/ml at 12 hours from symptom 
onset. Atypical symptoms were predefined as breathlessness, 
upper  back  pain  between  the  shoulder  blades,  epigastric 
discomfort or jaw pain in the absence of chest pain.
Data collection
This study was a retrospective case review. Obtained from the 
medical notes of these patients were the following:
Demographics: Age, sex, mode of admission (the mobile 
coronary care unit or via the emergency room etc.)
Risk  Factors:  History  of  hypertension,  diabetes  mellitus, 
family history of coronary disease, smoking, cholesterol, and 
body mass index.  
Delay Factors: Presentation delay was defined as longer than 
2 hours from onset of symptoms to first seeking medical 
assistance.  Treatment delay was defined as longer than 1 hour 
from when the patient first sought assistance to the initiation 
of appropriate medical therapy. Time of onset of symptoms 
(taken  from  the  patient  history),  time  of  ambulance  call 
(recorded on emergency room or mobile coronary care unit 
admission data) and time when seen by medical personnel 
were used to calculate delays.
Clinical  Factors: A  prior  history  of  MI  or  angina,  prior 
percutaneous coronary intervention (PCI) or coronary artery 
bypass grafting (CABG) were noted.
The site of infarction was determined from the admission 
ECG using standard Minnesota coding criteria.   NSTEMI was 
diagnosed if no ST elevation was present.  Echocardiography 
Ta b l e  I.
Baseline Characteristics of Male and Female Patients
Males (N=458) Females (N=205) P value
Age (yr)* 63±13 70±11 <0.001
No’s  % No’s  %
Family History 220 48 99 48 0.322
Diabetes Mellitus 74 16 42 20 0.166
Hypercholesterolaemia† 198 43 88 43 0.982
Hypertension 174 38 100 49 0.008
Smoking status-
Never smoked
Ex-smoker
Current smoker
108
166
184
24
36
40
80
51
73
39
25
36
<0.001
Body-mass index >25‡ 217 47 66 32 0.001
Past Medical History
Previous angina
Previous infarction
180
131
39
29
92
63
45
31
0.184
0.644
Previous Investigation
PCI
CABG
47
40
10
9
14
7
7
3
0.155
0.013
Total Cholesterol mmol/L* 4.8±1.2 5.2±1.2 <0.001
HDL mmol/L* 1.2±0.5 1.4±0.5 <0.001
LDL mmol/L* 2.8±1.1 3.2±1.1 0.002
Triglycerides mmol/L§ 1.52 1.67 0.327
Creatinine Clearance mls/min*  82±33 63±30 <0.001
*Mean ±SD †>5mmol/L ‡The body-mass index is the weight in kilograms divided by the square of the height in meters. Blood samples are fasting taken on 
day 2 of admission 
§ Median value – differences detected using the non parametric Mann Whitney U test. CABG = Coronary Artery Bypass Grafting, PCI = Percutaneous 
Coronary Intervention© The Ulster Medical Society, 2008.
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carried  out  (n  =  545)  within  48  hours  of  admission  was 
assessed.    LV  dysfunction  was  diagnosed  if  the  Ejection 
Fraction was <45%.
Laboratory Data: Fasting cholesterol and triglyceride levels 
on day two after admission and creatinine clearance were 
recorded for each patient.
Medical Therapy: Antiplatelet therapies including aspirin, 
clopidogrel and GPIIbIIIa inhibitors were noted.  Thrombolytic 
therapy  where  appropriate,  beta  blocking  therapy,  ACE 
inhibition and statin therapy were also recorded.
Coronary Angiography:  If  coronary  angiography  was 
performed  during  admission  or  within  three  weeks  after 
discharge it was noted as was revascularisation by PCI or 
CABG. The  extent  of  disease  at  angiography  i.e.  single, 
double or triple vessel disease was also documented.
Endpoint:  The  primary  endpoint  of  the  study  was  three 
month all cause mortality.  These data were obtained from the 
secondary prevention clinics or where this was unavailable, 
from  the  general  practitioner’s  records.   This  endpoint  at 
3 months post event was chosen to assess an intermediate 
mortality as other studies have assessed the early in hospital 
and 1 year mortality; it is however inclusive of in-hospital 
mortality.
Statistical analysis
All  analyses  were  performed  using  SPSS  version  11  for 
Windows;  SPSS  Inc,  Chicago,  Illinois,  USA).  Univariate 
comparison of dichotomous variables firstly by gender and 
then mortality was carried out using the Pearson’s χ2 statistic.   
Continuous normally distributed variables are reported as 
mean ± 1SD; median is quoted for data of skewed distribution.   
Normally  distributed  continuous  variables  were  similarly 
evaluated in terms of gender and then mortality using the 
Student’s  t  test.    Mann  Whitney  U  method  was  used  to 
compare non parametric continuous variables.  A p value of 
<0.05 was significant. 
Three  month  mortality  after  myocardial  infarction  was 
compared between men and women firstly without adjustment, 
then with adjustment for age and then with adjustment for age 
and other candidate variables identified on initial univariate 
analysis.  The models were constructed in a stepwise manner 
beginning with prehospital variables such as demographics 
and  risk  factors,  followed  by  delay  factors  and  clinical 
variables and finally with treatment given and interventions 
undertaken.  In each case sex was forced into the model.   
In this way the influence of gender on mortality could be 
evaluated in conjunction with confounding factors.  Results 
are  shown  as  odds  ratios  (OR)  with  corresponding  95% 
confidence intervals (CI).  The goodness of fit of the model 
was assessed by the Hosmer-Lemeshow statistic.
RESULTS
Baseline and presentation characteristics
Of the 663 AMI patients 31% (205) were female. Females 
were older (p<0.001), had a greater history of hypertension (p 
= 0.008) and smoked less than males (p<0.001).  A BMI >25 
was more frequent in the male group than in females (47% vs. 
32%, p=0.001).  Also the mean LDL was higher in the female 
group (3.2mmol/L vs. 2.8mmol/L, p = 0.002) (table I.)  
Women more commonly presented with atypical features than 
men (24% 49/205 versus 9% 41/458, p<0.001). There were 
no significant differences between males and females in their 
modes of presentation to coronary care; 63% (288/458) of 
males compared to 64% (132/205) of females were admitted 
via the emergency department and 37% (170/458) and 36% 
(73/205) respectively were admitted via the mobile coronary 
care unit. Similar numbers of males and females sought initial 
assistance from their general practitioner (12% 53/458 males 
versus 16% 33/205 females, p = NS).  Similar rates of delay 
were observed in both groups; 37% (170/458) males and 40% 
(81/205) females demonstrated a delay to present to medical 
services and 8% (36/458) males and 8% (16/205) females 
had some delay in initiation of therapy (p = 0.994). Baseline 
biochemical analysis for males and females is as shown in 
table 1.   Mean creatinine clearance in the female group was 
significantly lower than that of the male group (p<0.001) as 
would be expected given that creatinine clearance is closely 
related to age.
Fig 1.  Comparison of infarct location from admission 12 lead 
ECG in males and females*.
Fig 2.  Coronary angiography in males and females.© The Ulster Medical Society, 2008.
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Clinical factors and management instituted
ST  elevation  infarct  location  was  similar  in  males  and 
females.  There was however a preponderance of NSTEMI 
in females (51% 104/205 versus 41% 190/458 in males, p = 
0.023) (figure 1).  
Females did not receive aggressive antiplatelet therapies as 
often as males despite the higher prevalence of NSTEMI’s in 
this group (table II).  
Also, women did not proceed to diagnostic angiography and 
hence intervention as frequently as men (see figure 2).  This 
figure also demonstrates that the extent of atherosclerotic 
disease at catheterisation is similar in males and females.   
Females who were conservatively managed were significantly 
older  than  those  males  who  did  not  proceed  to  invasive 
investigation as shown in figure 3.  For those 365 male and 
137 female patients who did have diagnostic angiography, 
similar frequencies of males and females were successfully 
revascularised by either PCI (69% 253/365 males vs. 71% 
97/137  females)  or  CABG  (12%  42/365  males  vs.  8% 
11/137  females)  (p  =  NS).    LV  impairment 
occurred with similar frequency in both genders; 
28% 106/377 males compared to 30% 51/168 
females, p = 0.594.  
Three  month  mortality  in  females  was  11% 
(23/205) compared to 5% (24/458) in males (p = 
0.006). The age distribution of deceased patients 
is shown in figure 4.
Factors predictive of three month mortality
Table III summarises the results of a univariate 
analysis of three month mortality.  
Subsequent logistic regression models analysing 
the  influence  of  gender  on  mortality  in 
association  with  pre  hospital  variables  and 
also  with  treatment  factors  were  constructed.   
Table  IV  demonstrates  that  the  most 
significant  independent  predictors  of 
early  mortality  amongst  these  models 
are advanced age and presence of LV 
impairment. ST elevation infarction site 
was not included in this analysis as there 
were no significant differences between 
the genders for infarction site and to do 
so would have reduced the numbers of 
patients for analysis to a much smaller 
number.
The influence of gender on mortality 
after AMI
The  effect  of  sex  on  mortality  loses 
significance  when  age  is  added  in 
the  first  model.   As  age  was  such  a 
significant  confounding  variable  it  is 
subsequently  included  in  all  models. 
The frequency of LV impairment was 
similar in males and females, therefore 
we conclude that the observed excess in 
mortality amongst females is due to their 
advanced age.
DISCUSSION
These results highlight several differences in the presenting 
characteristics and subsequent management of myocardial 
infarction in men and women.  Potentially this information 
may  be  used  to  establish  a  gender  specific  approach  to 
diagnosis and management of CHD, so focusing services to 
better meet the needs of patients regardless of their gender. 
What  are  the  gender  differences  in  presentation  and 
management  of AMI?    Women  and  men  have  different 
disease perception; it is known that atypical symptoms such 
as epigastric discomfort, breathlessness and back pain are 
common presentations in women12,13. It is hypothesised that 
female patients are unaware that these symptoms can represent 
coronary ischaemia and so may fail to present to medical 
services in a timely fashion15,16. Our results do not support 
this theory but do show that a large proportion of our patients 
delay to present for significant periods of time regardless of 
their gender.  For those women who do present, theoretically 
there may be a delay in making the diagnosis and hence 
Ta b l e  II.
Initial Medical Therapy 
Treatment Male (N=458) Females (N=205) P value
No’s  % No’s  %
Thrombolytic given* 231 94 85 97 0.197
Aspirin therapy 433 95 194 95 0.952
Clopidogrel therapy 402 88 166 81 0.014
GP IIbIIIa Inhibitor therapy 67 15 18 9 0.037
LMWH/UFH 446 97 196 96 0.282
β blocking therapy 429 94 186 91 0.118
ACE inhibitor therapy 401 88 171 83 0.115
Statin therapy 444 97 199 97 0.829
*247 Males and 88 Females met Minnesota criteria for thrombolytic therapy and had no contraindication 
to thrombolytic therapy.  LMWH=Low Molecular Weight Heparin, UFH=Unfractionated Heparin
Fig 3.  Age distribution of males and females who did not have coronary 
angiography and were managed conservatively.© The Ulster Medical Society, 2008.
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Ta b l e  III.
Univariate Analysis of three Month Mortality
Deceased at 3 months (N=47) Alive at 3 months (N=616) P value
Age (yr)* 73±10 64±13 <0.001
No’s  % No’s %
Sex
Male
Female
24
23
51
49
434
182
71
29
0.006
Risk Factors:
Family History
Diabetes Mellitus
History of Hypercholesterolaemia†
Hypertension
Smoking status-
Never smoked
Ex-smoker
Current smoker
Body-mass index >25
20
10
19
25
17
19
10
14
43
21
40
53
36
40
21
30
299
106
267
249
171
198
247
269
48
17
43
40
28
32
40
44
0.763
0.435
0.788
0.047
0.048
0.198
Past Medical History:
Previous angina
Previous infarction
23
16
49
34
249
178
40
29
0.257
0.463
Previous Investigation:
PCI
CABG
3
5
6
11
58
42
9
7
0.486
0.327
Delay        Total  Delay
Presentation Delay
Treatment Delay
28
27
2
60
57
4
243
224
50
39
36
8
0.007
0.004
0.341
MI type:
STEMI
NSTEMI
25
22
53
47
344
272
56
44
0.724
ST elevation infarct site: N=369
Anterior
Inferior
Posterior
Lateral
Right Ventricular
8/25
11/25
5/25
1/25
32
44
20
4
149/344
179/344
7/344
7/344
2/344
43
52
2
2
1
<0.001
LV impairment:  N=545 21/36 58 136/509 27 <0.001
Treatment:
Thrombolytic therapy
Aspirin therapy
Clopidogrel therapy
LMWH/UFH therapy
GpIIbIIIa inhibition
ACE Inhibitor therapy
Β blocking therapy
Statin therapy
16
43
28
44
7
30
35
41
34
91
60
94
15
64
75
87
300
584
540
598
78
542
580
602
49
95
88
97
13
88
94
98
0.052
0.306
<0.001
0.135
0.659
<0.001
<0.001
<0.001
Coronary Angiography: N=502
PCI 
CABG 
19
8/19
4/19
4
42
21
483
342/483
49/483
96
71
10
<0.001
<0.001
0.956
Disease Extent at Angiography:
Normal Coronaries
Single Vessel Disease
Double Vessel Disease
Triple Vessel Disease
1/19
5/19
13/19
5
26
68
15/483
167/483
152/483
149/483
3
35
31
31
0.004
Total cholesterol mmol/L*
LDL mmol/L*
HDL  mmol/L*
Triglycerides  mmol/L§
Creatinine Clearance  mls/min*
N=29
4.4±1.3
2.6±1.2
1.2±0.5
1.2 (0.2)
N=36
40±31
N=539
5.0±1.3
3.0±1.1
1.2±0.5
1.6 (1.3)
N=585
74±36
0.009
0.129
0.988
0.001
<0.001
*Mean ±SD  †>5mmol/L  §Median (Variance) – Differences detected by the non parametric Mann Whitney U test CABG = Coronary Artery Bypass 
Grafting, HDL = High Density Lipoprotein, LDL = Low Density Lipoprotein, LMWH = Low Molecular Weight Heparin,  PCI = Percutaneous Coronary 
Intervention, UFH = Unfractionated Heparin© The Ulster Medical Society, 2008.
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initiation of therapy due to a combination of 
atypical histories and more NSTEMI’s13.   Again 
our results do not support greater treatment delay 
in females.  It is demonstrated that women have 
more hypertension and proportionately higher 
LDL  and  triglyceride  levels  than  the  men.   
Perhaps these risk factors impart more serious 
consequences to postmenopausal females than 
males  of  a  similar  age  particularly  when  the 
fact that females tend to have smoked less is 
considered.  Women are more likely to have a 
definite history of pre-infarct angina than men 
who tend to present initially with an infarct2,4.   
It  is  potentially  in  this  pre-infarct  stage  that 
intervention, both revascularisation techniques 
and risk factor management could be optimised 
in females.  Fig 4.  Age distribution of patients deceased at three months.
Ta b l e  IV .
The Influence of Gender on 3 Month Mortality By Logistic Regression*
P Value OR (95%CI)
Hosmer-Lemeshow 
statistic p value
Sex 0.007 2.29 (1.26-4.15)
Model 1 - Demographics
Sex
Age 
0.121
<0.001
1.64 (0.88-3.04)
1.06 (1.03-1.09)
0.702
Model 2 – Risk factors
Sex
Age
BP 
Smoking
0.210
0.001
0.18
0.44
1.51 (0.79-2.89)
1.05 (1.02-1.09)
1.53 (0.81-2.87)
0.85 (0.56-1.29)
0.733
Model 3 - Delay
Sex 
Age
Presentation Delay
0.133
<0.001
0.015
1.62 (0.86-3.02)
1.06 (1.03-1.09)
2.14 (1.16-3.97)
0.381
Model 4 – Disease factors
Sex
Age
LV impairment
0.100
0.009
<0.001
1.83 (0.90-3.75)
1.05 (1.01-1.08)
0.28 (0.13-0.56)
0.219
Model 5 – Treatment factors
Sex 
Age 
Clopidogrel therapy
β Blocking therapy
ACE Inhibitor therapy
Statin therapy
0.197
0.002
0.010
0.006
0.005
0.090
1.54 (0.80-3.00)
1.05 (1.02-1.08)
0.40 (0.20-0.80)
0.31 (0.13-0.71)
0.35 (0.17-0.73)
0.32 (0.09-1.20)
0.410
Model 6- Intervention
Sex
Age
Angiography
PCI
0.147
0.080
0.070
0.030
1.61 (0.85-3.06)
1.03 (1.00-1.06)
0.48 (0.22-1.06)
0.35 (0.13-0.91)
0.798
*Creatinine clearance was not included as its value is largely a function of age.© The Ulster Medical Society, 2008.
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Is  the  “discrimination”  against  women  in  terms  of 
investigation and management real? 
ST  elevation  infarct  site  and  presence  of  post  infarct  LV 
impairment  is  similar  in  men  and  women.    Consistent 
with  previous  reports  highlighting  discrepancies  in 
invasive investigation and management between males and 
females10,11,14, this  is  confirmed  in  our  patient  population. 
This also contributes to the shortfall in the administration 
of aggressive antiplatelet agents in women.  Figure 3 shows 
that those women who were managed conservatively were 
much older than males posing the question that perhaps there 
are younger males who may have benefited from invasive 
investigation. Contrary to the opinion that women have less 
intervention potential due to their smaller arteries, distribution 
of disease and comorbidities, we have demonstrated that those 
females selected for angiography have similar disease extent 
and revascularisation outcomes to the males. These women 
are however a selected group in real practice; this may prove 
to be the best management approach and not a reflection of 
“discrimination” towards the female gender.  
When adjusted for confounding variables gender no longer 
has  an  influence  on  survival  after  myocardial  infarction 
regardless of the management strategy.  The advanced age 
of the females largely explains the excess in three month 
mortality observed in this group.
Implications for future policies on management of CHD 
in women: 
As our Western population continues to age so the burden 
of ischemic heart disease in women is increasing. Mortality 
after myocardial infarction is indeed higher in women and 
so the challenge presents to prevent myocardial infarction 
where possible by targeting modifiable factors in the pre-
infarct  stage.  Traditionally  guidelines  on  the  diagnosis 
and management of ischemic heart disease have made few 
allowances for the differences in presentation and natural 
history of the disease between the genders.  In the light of 
these results and those of previous studies it follows that we as 
physicians are not adhering to the current guidelines7,9,11,13,14,17. 
Is this appropriate?  Until recent years coronary heart disease 
was predominantly a male disease and the large clinical trial 
data have reflected this experience with only small numbers 
of females recruited. Our study has not specifically examined 
diagnostic investigations, but it is demonstrated in the WISE 
study18 and others19-21 that diagnostic strategies have different 
sensitivity  specificity  ratios  in  females  as  compared  to 
males, further compounding the confusion in diagnosis and 
substantiating the myth that females are not at risk of CHD. 
Also whilst it is reasonable to extrapolate findings from large 
meta-analyses on the standard pharmacological therapies to 
female patients, it is important to recognise that gender related 
differences in metabolism and action of these medications 
often have important clinical effects22.  It is also accepted that 
women have more complications following PCI or CABG 
however this opinion is based on registry observations and 
there are few clinical trials powered sufficiently to detect a 
significant outcome difference between the sexes23-26. Some 
conflicting studies determined that women have equal5,6 if not 
more benefit from PCI27.  Trial data on patients over 75 years 
of which women make up the majority are scarce.  For this 
reason guidelines based on existing data should be interpreted 
with caution in the real life scenario, particularly with regard 
to elderly female patients.
It  is  likely  that  when  armed  with  information  such  as  is 
presented in this study we will appreciate that a gender specific 
approach  to  the  diagnosis  and  management  of  ischemic 
heart disease will be more effective in the future.  One such 
approach will take account of the diagnostic limitations of 
the exercise stress test in females and make better use of 
other more sensitive and specific investigations in this group 
such as dobutamine stress echocardiography and myocardial 
perfusion imaging. Very aggressive risk factor modification, 
in particular hypertension and cholesterol management, may 
have more marked benefits in women than men in terms of 
prevention of fatal myocardial infarction. Selection of female 
patients after myocardial infarction for intervention should 
take into consideration comorbidities and the risk benefit ratio 
of intervention in women. Disease perception and awareness 
is  a  persistent  problem  amongst  females.  The American 
Heart Association’s “Go red for women” and the European 
Cardiology Society’s “Women at heart” initiatives should help 
to raise awareness of these issues and implement appropriate 
changes in management strategy.
Study limitations
Several limitations should be recognised.  The numbers of 
patients achieving the endpoint of three month mortality are 
relatively small in both males and females.  This is clearly a 
reflection of the improved management strategies in recent 
years but may have implications on regression models for 
identification  of  independent  predictors  of  mortality.  We 
do however feel that the model devised is reliable in that 
advanced age accounted for the vast majority of the gender 
discrepancy. We did not take account of pre hospital mortality 
which is recognised to be higher in males than in females10. 
Not all of the patients had a 48 hour echo carried out (82% 
545/663)  therefore  we  do  not  have  complete  data  on  LV 
function.  However identical proportions of each gender had 
an  echo  completed  (82%  377/458  men  vs.  82%  168/205 
women). Also,  the  logistic  regression  models  devised  on 
SPSS utilise only patients with complete data for the variable 
under examination and so we feel the models to be accurate 
and reliable.
CONCLUSIONS 
Three month mortality after myocardial infarction in women 
is higher than that of men (11% vs. 5%). Women (70 ± 11 
years) were significantly older than men (63 ± 13 years). 
Whilst  women  after  myocardial  infarction  are  less  likely 
than men to undergo invasive cardiac catheterisation (67% 
137/205 vs. 80% 365/458) successful revascularisation rates 
were similar (71% 97/137 women had PCI vs. 69% 255/365 
men and 8% 11/137 women had CABG vs. 12% 42/365 men). 
Independent predictors of three month mortality were age and 
left ventricular impairment.  As left ventricular impairment 
was comparable in men and women, the excess mortality 
observed in females was mainly due to their older age at 
presentation.
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